Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

endpts.com

ENDPOINTS NEWS

Get the latest updates from ENDPOINTS NEWS directly as they happen.

Follow now 168 followers

Latest posts

Last updated about 6 hours ago

Sarepta says it won't pull Duchenne gene therapy, setting up showdown with FDA

about 6 hours ago

Sarepta Therapeutics said it won't comply with an FDA request to stop...

FDA adcomm votes against Otsuka's Rexulti-Zoloft combo for PTSD

about 10 hours ago

The FDA’s Psychopharmacologic Drugs Advisory Committee on Friday voted 10-1 against the...

Sail Bio cuts staff by 30% and trims leadership team

about 11 hours ago

Sail Biomedicines, a well-funded startup that once aspired to become Moderna 2.0...

Peter Marks says Sarepta gene therapy pause 'makes sense'

about 11 hours ago

Former CBER chief Peter Marks says that a decision to pause shipments...

FDA rejects expanded label for Roche's Columvi

about 12 hours ago

The FDA issued a complete response letter to Roche’s Columvi, saying the...

FDA asks Sarepta to stop selling Duchenne treatment, following patient deaths

about 13 hours ago

The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy...

David Baker’s lab uses AI to help catch nature’s squirmiest proteins

about 15 hours ago

In the wide world of traditionally undruggable proteins, one group stands out...

Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes

about 15 hours ago

Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics Bristol Myers Squibb...

Viatris’ ophthalmic drug flunks Phase 3 study, company mulls next steps

about 16 hours ago

Viatris said Friday its treatment candidate for a common form of eye...

#IAS25: HIV activists, scientists press for change, fueled by excitement for new PrEP tools

about 16 hours ago

KIGALI, RWANDA — Emotions ran high this week at one of the...

Bill Anderson to stay on at Bayer; C-suite changes at troubled Sarepta

about 19 hours ago

Lots to recap this week for Peer Review → Bayer CEO Bill...

Sarepta patient dies in study for limb-girdle muscular dystrophy, raising more safety concerns

1 day ago

Sarepta Therapeutics said that a patient died in a clinical trial testing...